FDA scientists flag evidence gaps in peptides ahead of July compounding panel
A federal advisory panel will weigh whether compounding pharmacies can again make peptides such as BPC-157 and TB-500, even as FDA scientists say the evidence for their safety and benefit is thin.
FDA scientists say there is not enough evidence to support loosening restrictions on seven peptides that a federal advisory panel will review next month. Documents the agency posted on June 29 flag potential safety concerns and inconsistent data for the substances, which include BPC-157, TB-500 and MOTs-C [1].
Peptides are strings of amino acids, smaller than a protein, that the body makes naturally. The GLP-1 weight loss drugs are examples of synthetic peptides [1]. The peptide therapies promoted online for wellness and longevity have not gone through large-scale, rigorous clinical trials in humans, and are typically taken as a subcutaneous injection to help with injuries, muscle recovery, metabolism and more [1].
The Pharmacy Compounding Advisory Committee is scheduled to meet July 23 and 24 to review the evidence for the seven peptides, for specific uses that include ulcerative colitis, wound healing, obesity and migraines [1]. The panel is expected to make recommendations on those seven and then reconvene in February to consider others [1]. It is unclear how the panel will weigh the findings of the FDA's career scientists, who concluded there is insufficient evidence to change the designation for any of the seven [1].
In 2023, the Biden administration placed restrictions on these and a handful of other peptides, moving them into a category that essentially prohibits compounding pharmacies from making the drugs [1]. Since then, many peptide users have turned to a gray market, often sourcing products from sketchy suppliers overseas [1].
Health Secretary Robert F. Kennedy Jr. has said he has used some peptides himself and wants the FDA, which is overseen by the Department of Health and Human Services, to allow compounding pharmacies to offer them again [1]. The panel includes members with ties to the peptide industry, among them people who work for companies that offer injectable peptides [1].
"Not a day goes by where I don't have a number of patients asking me about peptides," said Dr. Alexander Weber, an orthopedic surgeon and chief of sports medicine at the University of Southern California who has published a review of the evidence. "My stock answer is that we just don't have enough data to support their use." [1]
Why it matters for patients
The documents concern compounded peptide products, not the FDA-approved GLP-1 medicines that are also synthetic peptides [1]. What could change is what licensed compounding pharmacies are allowed to make. Right now, people who want these peptides often buy them through the gray market rather than from a pharmacy [1]. FDA scientists say the safety and efficacy data do not support moving them back into the category that permits compounding [1].
That leaves patients with little to go on. Weber's review and the FDA documents point to the same gap, and the agency's conclusion echoes what other reviewers have found [1]. Whether the committee's recommendations will change agency policy has not been reported.
What happens next
The Pharmacy Compounding Advisory Committee meets July 23 and 24, 2026, and is expected to make recommendations on seven peptides [1]. A second meeting is planned for February to take up others [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.